Company intelligence / Profile preview

ARMRA

Ownership: Private
Employees: ~90
Development stage: Commercial

Overview

ARMRA has commercialized a patented bovine colostrum concentrate using proprietary cold-extraction technology that preserves over 200–400 bioactive nutrients. The product aims to restore immune barriers compromised by modern living and has been well received for its safety standards and scientific rigor. Clinical results are not detailed but the company references extensive research supporting the benefits of colostrum supplementation for gut and immune health[1][2].

Therapeutic areas: GastroenterologyMetabolic DisordersImmunologyDermatologyNeurology
Modalities: Bovine colostrum concentrate (bioactive food/superfood supplement)
Industry: Food & Nutrition

Drug pipeline

1 asset

colostrum supplement

Commercial

Indications: General wellness, Immune support

Partnerships

CarbonFund.org as a Carbonfree® Business partner for carbon offsetting[1]

Beyond the preview

Go deeper on ARMRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARMRA.

Explore the full profile